# Keith Murphy

> Keith Murphy is a chemical engineer, biotech founder, inventor, and investor whose career runs from drug-development work at Alkermes and Amgen to founding Organovo and Viscient Biosciences. He co-invented the NovoGen MMX bioprinter and now serves as founder, CEO, and chairman of Viscient as well as executive chairman of VivoSim Labs, where his long-running thesis is that human 3D tissue models can make preclinical drug decisions more predictive.

- **Role:** Founder, CEO and Chairman at Viscient Biosciences; Executive Chairman at VivoSim Labs
- **Organizations:** Viscient Biosciences, VivoSim Labs, Organovo, Amgen, Alkermes, No Patient Left Behind, California Life Sciences Association
- **Education:** B.S. in Chemical Engineering, Massachusetts Institute of Technology, Alumnus, UCLA Anderson School of Management
- **Known for:** Co-invented the NovoGen MMX bioprinter platform., Founded Organovo in 2007 and led the company through its 2012 public listing., Helped develop Organovo's early pharmaceutical partnerships and commercial 3D tissue work.

## Career timeline

- **Before 1997** — Worked at Alkermes and contributed to the development of a once-monthly human growth hormone program with Genentech.
- **1997-2007** — Spent ten years at Amgen in roles of increasing responsibility, including four years as global operations leader for denosumab.
- **2007** — Founded Organovo and began leading its operations.
- **2012** — Organovo became public; Murphy served as president, CEO, and chairman during its early public-company period.
- **2017** — Left Organovo's operating leadership and co-founded Viscient Biosciences with Jeffrey Miner.
- **2020** — Rejoined the Organovo board in July and became executive chairman in September.
- **2025** — Continued as executive chairman as Organovo adopted the VivoSim Labs name and VIVS ticker.
- **2026** — Serves as VivoSim Labs executive chairman directly overseeing operations while remaining CEO and founder of Viscient Biosciences.

## Achievements

- Co-invented the NovoGen MMX bioprinter platform.
- Founded Organovo in 2007 and led the company through its 2012 public listing.
- Helped develop Organovo's early pharmaceutical partnerships and commercial 3D tissue work.
- Founded Viscient Biosciences in 2017 to use 3D human tissue and multi-omics in drug discovery.
- Testified before a U.S. House subcommittee in 2017 about 3D bioprinted human tissue models.
- Serves as co-chair of the No Patient Left Behind advisory board.
- Organovo was named a 2015 Technology Pioneer by the World Economic Forum during his tenure.

## Latest updates

- **2026-07** — Signed a placement agency agreement in his capacity as executive chairman of VivoSim Labs.
- **2026-03** — Signed VivoSim Labs' Form S-1 registration statement as executive chairman and principal executive officer.
- **2025-07** — Appeared on the D.C. Download podcast to discuss New Approach Methodologies and human-focused drug testing.
- **2025-04** — Organovo adopted the VivoSim Labs name and positioned its work around human-relevant preclinical models.

## Links

- Website: https://viscientbiosciences.com
- LinkedIn: https://www.linkedin.com/in/kemurph

---

Profile page: https://yespress.io/keith-murphy
Published by YesPress — https://yespress.io
Last updated: 2026-08-27